An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC.
Radiopharmaceutical Therapy Targeting PSMA for Prostate Cancer
Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should know before, during and after the scan.
Joseph Wood, a patient, and Deborah Wood, Joseph’s wife and caregiver, talk about Joseph’s prostate cancer diagnosis and Deborah explains her role as a caregiver.
Dr Matthew Rettig reviews the front-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and what factors are considered when choosing appropriate treatment.
Dr Jeremie Calais talks about the emergence and importance of PSMA-targeted radioligand therapy.
Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).
Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood.
Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).
Drs Matthew Rettig and Jeremie Calais explain what it means to be a part of a collaborative team and how communication plays a big role in patients receiving optimal treatment.
Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.
Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community.
